ANASTASIA MEDRANO: Open Payments
NPI 1457132862 · MIDLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$788 in 43 payments from 9 companies in 2025. Trend: 2023 $96 · 2024 $1,001 · 2025 $788
Food & beverage: $788
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $229 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $163 |
| E.R. Squibb & Sons, L.L.C. | 4 | $106 |
| Merck Sharp & Dohme LLC | 4 | $85 |
| AstraZeneca Pharmaceuticals LP | 4 | $73 |
| Alnylam Pharmaceuticals Inc. | 2 | $52 |
| SCPHARMACEUTICALS INC. | 2 | $31 |
| Novartis Pharmaceuticals Corporation | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
Products named: REPATHA, JARDIANCE, CAMZYOS, FARXIGA, VERQUVO, AMVUTTRA, FUROSCIX, ELIQUIS.
Industry payments across TX — which companies pay providers there.
